Lincoln National Corporation (LNC)
NYSE: LNC · Real-Time Price · USD
36.87
-1.24 (-3.25%)
Aug 1, 2025, 4:00 PM - Market closed
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Hold" and an average price target of $38.78, which forecasts a 5.18% increase in the stock price over the next year. The lowest target is $35 and the highest is $44.
Price Target: $38.78 (+5.18%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 8 | 8 | 9 | 9 | 9 | 8 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 11 | 11 | 11 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $33 → $35 | Hold | Maintains | $33 → $35 | -5.07% | Jul 10, 2025 |
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Hold Maintains $39 → $40 | Hold | Maintains | $39 → $40 | +8.49% | Jul 9, 2025 |
| JP Morgan | JP Morgan | Sell Maintains $38 → $41 | Sell | Maintains | $38 → $41 | +11.20% | Jul 8, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $32 → $38 | Hold | Maintains | $32 → $38 | +3.06% | May 19, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $38 → $36 | Hold | Maintains | $38 → $36 | -2.36% | May 9, 2025 |
Financial Forecast
Revenue This Year
19.03B
from 17.97B
Increased by 5.92%
Revenue Next Year
19.63B
from 19.03B
Increased by 3.16%
EPS This Year
7.23
from 18.41
Decreased by -60.73%
EPS Next Year
7.69
from 7.23
Increased by 6.38%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 20.0B | 21.0B | 21.4B | |
| Avg | 19.0B | 19.6B | 20.1B | |
| Low | 18.1B | 18.5B | 19.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 11.5% | 10.5% | 8.8% | |
| Avg | 5.9% | 3.2% | 2.6% | |
| Low | 0.8% | -2.7% | -2.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 7.88 | 8.40 | 9.71 | |
| Avg | 7.23 | 7.69 | 8.47 | |
| Low | 6.62 | 7.15 | 7.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -57.2% | 16.2% | 26.3% | |
| Avg | -60.7% | 6.4% | 10.2% | |
| Low | -64.1% | -1.1% | -4.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.